Combined-modality therapy for early-stage Hodgkin lymphoma: Maintaining high cure rates while minimizing risks

ONCOLOGY (United States)

Volumn 26, Issue 12, 2012, Pages

  Kelsey, Chris R ^a   Beaven, Anne W ^b   Diehl, Louis F ^b   Prosnitz, Leonard R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUMC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; DRUG FATALITY; ERYTHROCYTE SEDIMENTATION RATE; EVENT FREE SURVIVAL; HEART DISEASE; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; INFECTION; LOW ENERGY RADIATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERICARDITIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION FIELD; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SECOND CANCER; TUMOR VOLUME;

EID: 84874602870     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Peters MV. A study of survivals in Hodgkins disease treated radiologically. Am J Roentgenol Radium Ther. 1950;63:299-311.
2. Kaplan HS. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkins disease. Cancer Res. 1966;26:1221-4.
3. Rosenberg SA, Kaplan HS. Evidence for an orderly progression in the spread of Hodgkin's disease. Cancer Res. 1966;26:1225-31.
4. Koontz BF, Kirkpatrick JP, Clough RW, et al. Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. J Clin Oncol. 2006;24:605-11.
5. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkins disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101-8.
6. Aviles A, Delgado S. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkins disease with bulky disease. Clin Lab Haematol. 1998;20:95-9.
7. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkins disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol. 2004;22:62-8.
8. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkins lymphoma. N Engl J Med. 2012; 366:399-408.
9. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkins disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765-71.
10. Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkins lymphoma (HL). J Clin Oncol. 2005;23(16S): abstr 6505.
11. Pavlovsky S, Maschio M, Santarelli MT, et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkins disease. J Natl Cancer Inst. 1988;80:1466-73.
12. Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkins lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48:1721-7.
13. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104:3483-9.
14. Wolden SL, Chen L, Kelly KM, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with hodgkins lymphoma--a report from the Childrens Oncology Group. J Clin Oncol. 2012; 30:3174-80.
15. Franklin JG, Paus MD, Pluetschow A, et al. Chemotherapy, radiotherapy and combined modality for Hodgkins disease, with emphasis on second cancer risk. Cochrane Database Syst Rev. 2005(4): CD003187.
16. Pavone V, Ricardi U, Luminari S, et al. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkins lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Ann Oncol. 2008;19:763-8.
17. Engert A. Radiotherapy in early-stage Hodgkin lymphoma. The ASCO Post. June 15, 2012.
18. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkins lymphoma: results of the HD8 trial of the German Hodgkins Lymphoma Study Group. J Clin Oncol. 2003;21:3601-8.
19. Zittoun R, Audebert A, Hoerni B, et al. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkins disease. J Clin Oncol. 1985;3:207-14.
20. Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkins disease: long-term results. J Clin Oncol. 2004;22:2835-41.
21. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkins lymphoma: a question of field size. J Clin Oncol. 2008;26:5170-4.
22. Eich HT, Muller RP, Engenhart-Cabillic R, et al. Involved-node radiotherapy in early-stage Hodgkins lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol. 2008;184:406-10.
23. Girinsky T, Specht L, Ghalibafian M, et al. The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol. 2008;88:202-10.
24. Prosnitz LR, Farber LR, Fischer JJ, et al. Low dose radiation therapy and combination chemotherapy in the treatment of advanced Hodgkins disease. Radiology. 1973;107:187-93.
25. Loeffler M, Diehl V, Pfreundschuh M, et al. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkins disease. J Clin Oncol. 1997;15:2275-87.
26. Arakelyan N, Jais JP, Delwail V, et al. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial. Cancer. 2010;116:4054-62.
27. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkins lymphoma. N Engl J Med. 2010;363:640-52.
28. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkins lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28:4199-206.
29. Elconin JH, Roberts KB, Rizzieri DA, et al. Radiation dose selection in Hodgkin's disease patients with large mediastinal adenopathy treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 2000;48:1097-105.
30. Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkins disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008;72:24-33.
31. De Bruin ML, Sparidans J, vant Veer MB, et al. Breast cancer risk in female survivors of Hodgkins lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27:4239-46.
32. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkins disease. JAMA. 1993;270:1949-55.
33. Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831-7.
34. Inskip PD, Robison LL, Stovall M, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol. 2009;27:3901-7.
35. Kupeli S, Hazirolan T, Varan A, et al. Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkins lymphoma. J Clin Oncol. 2010;28:1025-30.
36. Salloum E, Doria R, Schubert W, et al. Second solid tumors in patients with Hodgkins disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol. 1996;14:2435-43.
37. Sasse S, Klimm B, Görgen H, et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended-or involved-field radiotherapy in early-stage Hodgkins lymphoma. Ann Oncol. 2012;23:2953-9.
38. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer. 2010;55:1145-52.
39. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25:1489-97.
40. OBrien MM, Donaldson SS, Balise RR, et al. Second malignant neoplasms in survivors of pediatric Hodgkins lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010;28:1232-9.
41. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109:1878-86.
42. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49: 1486-93.
43. Glanzmann C, Kaufmann P, Jenni R, et al. Cardiac risk after mediastinal irradiation for Hodgkins disease. Radiother Oncol. 1998;46:51-62.
44. von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkins lymphoma: final analysis of the German Hodgkin study group HD14 trial. J Clin Oncol. 2012;30:907-13.